Tag Archive for: ISA101b

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy

/in

First-in-human study investigating the safety and immunogenicity of ISA’s proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs). SLPs conjugated to Amplivant elicit a significant, strong immune response and dose related systemic T cell immunity when injected intradermally. Study demonstrates that SLPs conjugated to Amplivant have highly favourable tolerability and […]

Read more

Professor Melief to receive 2022 SITC Pedro J. Romero Award

/in

The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy field Second SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro […]

Read more

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

/in

Recognition of commendable, longstanding dedication to the field of cancer immunotherapy Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of […]

Read more

ISA Pharmaceuticals long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor

/in

Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (ISA101b + anti-PD1) Deep and durable responses have a profound positive effect on patient prognosis with patients disease-free for more than 44 months Improved tumour infiltration by immune cells predicted response to therapy Oegstgeest, March 1, 2022 – ISA today announces the publication of […]

Read more